Rocket Lab Eyeing Semiconductors Expansion – Inks Initial Pact Worth $23.9M For CHIPS Act Funding

Rocket Lab secures $23.9M CHIPS Act funding to expand semiconductor production for critical space missions.

On Tuesday, Rocket Lab USA, Inc. (NASDAQ:RKLB) inked a non-binding preliminary memorandum of terms with the Department of Commerce.

Under the deal, Rocket Lab will receive up to $23.9 million in direct funding under the CHIPS and Science Act.

This CHIPS investment would create more than 100 direct manufacturing jobs.

“Semiconductors are central to modern life, to our economy, and to America’s future. We are proud to be strengthening that future with the support of the CHIPS Office by expanding our production facilities to meet growing demand for the semiconductors that power the nation’s most critical science, defense and commercial space missions,” said Rocket Lab founder and CEO Sir Peter Beck. 

Rocket Lab has indicated that it plans to claim the Department of the Treasury’s Investment Tax Credit, which is expected to be up to 25% of qualified capital expenditures.

The investment would enable Rocket Lab to increase its production of compound semiconductors for spacecraft and satellites as part of an expansion and modernization of the company’s facility in Albuquerque, New Mexico.

Rocket Lab also sees a rise in its resilient supply of space-grade solar cells following the development.

The modernization and expansion project would also increase Rocket Lab’s compound semiconductor production by 50% within the next three years, helping to domestically meet the growing national security and consumer demand for these solar cells.

Price Action: RKLB shares are trading lower by 0.56% to $4.534 at last check Tuesday.

Read Next: Tesla Rival Rivian Rolls Out Next-Gen R1S And R1T: Enhanced Performance, Design, And Tech Start At $69,900

Total
0
Shares
Related Posts
Read More

CBD-Focused Pharma Co. Innocan Reveals 433% YoY Increase In 2023 Revenue As It Pursues FDA Approval

Cannabinoid-focused pharmaceutical company Innocan Pharma Corp expects preliminary revenues of $4.89m in Q4 of fiscal 2023, representing a YoY increase of 331%. It said preliminary revenues are expected to be at least $13.6m for the whole of the fiscal year, a 433% YoY increase. Its subsidiary B.I. Sky Global drove the increase in sales. Innocan is currently pursuing FDA approval for its human pharmaceutical applications following successful pre-clinical trials, and the company expects pre-investigational new drug applications to be submitted to the FDA before the end of the month. Innocan has developed a long-lasting and therapeutic liposomal formulation for CBD called LPT Solution, which administers injectable CBD encapsulated in liposomes to achieve long-lasting therapeutic levels of CBD in the body. The company said the technology creates a more effective and prolonged therapeutic effect. Innocan plans to test the LPT platform on a new animal species in the near future.

CSE:INNO